Diagnosis and Treatment of Keratoderma
For hereditary palmoplantar keratoderma (PPK), obtain genetic testing via whole-exome or genome sequencing to establish diagnosis and guide management, as this identifies disease-causing variants in 83% of cases and is critical for detecting life-threatening associations like cardiomyopathy with DSP variants 1.
Diagnostic Approach
Clinical Classification
Keratodermas are categorized by:
- Distribution pattern: Diffuse (34%), punctate (55%), focal (7%), or striate (4%) 1
- Hereditary vs. acquired: Distinguish based on family history, age of onset, and associated features 2
- Syndromic features: Look specifically for cardiac symptoms (DSP-related cardiomyopathy risk), cystic fibrosis, or systemic disease associations 1
Genetic Testing Strategy
Genetic testing should be performed early in the diagnostic workup 1. The 2025 Danish cohort study identified pathogenic variants in 13 genes, with AAGAB variants showing perfect correlation with punctate PPK 1. This is clinically actionable because:
- DSP variants require cardiac screening and monitoring
- AAGAB variants predict punctate subtype with 100% specificity
- Diffuse, focal, and striate subtypes show more complex genotype-phenotype patterns requiring broader genetic panels 1
Acquired Keratoderma Evaluation
For suspected acquired cases, systematically evaluate:
- Medication history: Drug-induced keratoderma
- Hormonal status: Keratoderma climactericum in menopausal women 3
- Underlying malignancy: Paraneoplastic associations 2
- Infectious triggers: Particularly in reactive arthritis with keratoderma blennorrhagicum 4
Treatment Algorithm
First-Line Topical Therapy
Start with keratolytics combined with emollients 5. The 2024 European guidelines establish this as foundational:
- Urea 10-40%: Most commonly used keratolytic, requiring ≥10% for keratolysis and up to 40% for localized thickening (joints, palmoplantar areas) 5
- Alpha-hydroxyacids or propylene glycol: Alternative keratolytics when urea is not tolerated 5
- Application: Once or twice daily, tapered based on response 5
Critical safety considerations:
- Salicylic acid and lactic acid are strictly contraindicated under age 2 years due to life-threatening toxicity risk 5
- Urea should not be used in the neonatal period except on very limited areas (palms/soles only) 5
- All keratolytics are relatively contraindicated in first 6-12 months due to immature stratum corneum and increased systemic absorption 5
Second-Line Topical Options
Tazarotene (0.05-0.1%) is recommended as first-line to reduce scaling or skin thickening and avoid systemic therapy 5. The 2024 guidelines prioritize this based on:
- Efficacy demonstrated in multiple CI forms including open studies and case series 5
- Long-term use shows no detectable plasma levels in most patients 5
- Availability may be limited by cost and off-label use 5
Calcipotriol: Moderately efficacious in adults (up to 100g/week), but use with caution in children due to limited safety data 5
Systemic Therapy
Oral retinoids appear most efficient for severe or refractory cases 6, though efficacy varies by PPK subtype and tolerance is variable. The 2021 review emphasizes this as the most effective systemic option when topical therapy fails 6.
Special Populations
Keratoderma climactericum (menopausal women): Consider topical estriol 0.125 mg/g cream combined with urea 50% and clobetasol propionate 0.05% 3. The 2018 case report showed marked improvement with this hormonal approach, supporting the local estrogen deficiency hypothesis.
Reactive arthritis with keratoderma blennorrhagicum: If conventional DMARDs and biologics fail, tofacitinib (JAK inhibitor) demonstrates remarkable efficacy 4. The 2024 case report showed significant improvement within 20 days when adalimumab and secukinumab worsened the condition.
Critical Pitfalls to Avoid
Missing cardiac screening in DSP-related PPK: Always obtain echocardiography and cardiology consultation when DSP variants are identified 1
Keratolytic toxicity in infants: The immature epidermal barrier and higher body-surface-to-mass ratio dramatically increases systemic absorption risk. Salicylic acid has caused life-threatening toxicity in young children 5
Assuming all diffuse PPK is the same: The 2025 genetic study reveals that diffuse, focal, and striate subtypes involve 12 different genes with complex patterns, requiring comprehensive genetic testing rather than targeted single-gene analysis 1
Overlooking malignancy in acquired PPK: Systematically evaluate for underlying malignancy in adult-onset acquired keratoderma without clear alternative etiology 2